ANITA BELLAIL
president HB Therapeutics, Inc.
Dr. Anita Bellail is the President and Chief Scientific Officer of HB Therapeutics, a biotechnology company pioneering targeted protein degradation strategies to address oncogenic drivers such as KRAS mutants. With over 20 years of experience in the field of protein degradation, Dr. Bellail has led groundbreaking work in the discovery and development of molecular glue degraders and E3 ligase biology. Her leadership at HB Therapeutics is focused on advancing first-in-class therapeutics by harnessing novel degradation mechanisms to tackle previously undruggable targets in cancer.
Seminars
